Abstract
Background Behavioural and cognitive interventions remain a credible approach in preventing loneliness and depression. There was a need to rapidly generate and assimilate trial-based data during COVID-19.
Objectives We undertook a COVID-19 parallel pilot RCT of behavioural activation for depression and loneliness [the BASIL-C19 trial ISRCTN94091479]. We also assimilate these data in a COVID-19 living systematic review [PROSPERO CRD42021298788].
Methods Primary care participants (>=65 years) with long-term conditions were computer randomised to Behavioural Activation (n=47) versus care-as-usual (n=49). The single blinded primary outcome was the PHQ-9. Secondary outcomes included loneliness (De Jong Gierveld Scale). Data from the BASIL-C19 trial were included in a random effects meta-analysis of depression and loneliness.
Findings The 12 months adjusted mean difference for PHQ-9 was -0.70 (95% CI -2.61 to 1.20) and for loneliness was -0.39 (95% CI -1.43 to 0.65). Secondary 12-month trial outcomes suggested evidence of benefit for behavioural activation.
The BASIL-C19 meta-analysis (13 trials) found short-term reductions in depression (standardised mean difference [SMD]=-0.31, 95%CI -0.51 to -0.11) and loneliness (SMD=-0.48, 95%CI -0.70 to -0.27). There were few long-term trials, but there was evidence of some benefit (loneliness SMD=-0.20, 95%CI -0.40 to -0.01; depression SMD=-0.20, 95%CI -0.47 to 0.07).
Discussion We found a signal of effect in reducing loneliness and depression in the BASIL trial. Living meta-analysis provides strong evidence of short-term benefit for loneliness and depression.
Clinical implications Scalable behavioural and cognitive approaches should be considered as population-level strategies for depression and loneliness on the basis of the living systematic review.
Funding This study was funded by National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research (PGfAR) RP-PG-0217-20006.
Why was this study done?
⍰ Older people with long-term conditions have been impacted by COVID-19 pandemic restrictions and have experienced social isolation. In turn, this puts them at risk for depression and loneliness, and these are bad for health and wellbeing. Psychosocial approaches, such as behavioural activation, could be helpful.
⍰ Trial-based evidence is needed to demonstrate if it is possible to prevent the onset, or mitigate the impact, of loneliness and depression.
⍰ There are few studies of brief psychosocial interventions to mitigate depression and loneliness, and it is important to know how emerging trial-based data adds to existing evidence.
What did the researchers do and find?
⍰ There was preliminary evidence that levels of loneliness were reduced at 3 months when behavioural activation was offered.
⍰ At longer term (12-month) follow-up there were signals of ongoing positive impact.
⍰ When BASIL-C19 data were assimilated into a living systematic review there is clear evidence of impact of brief psychological interventions on depression and loneliness in the short-term. More research into the longer-term impact is needed.
What does all this mean?
⍰ Behavioural activation now shows evidence of benefit which will be useful for policy makers in offering support to people who are socially isolated.
⍰ This research knowledge will be useful once the COVID-19 pandemic has passed, since loneliness is common in older populations and effective scalable solutions will be needed to tackle this problem.
⍰ As new trial-based data emerges, our living systematic review and meta-analysis will be updated since this is an area of active research.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
ISRCTN94091479
Clinical Protocols
https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1003779
Funding Statement
This study was funded by National Institute for Health and Care Research (NIHR) Programme Grants for Applied Research (PGfAR) RP-PG-0217-20006.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the BASIL-C19 study was granted by Yorkshire & The Humber - Leeds West Research Ethics Committee on 23/04/2020 (The Old Chapel, Royal Standard Place, Nottingham, NG1 6FS, UK; +44 (0)207 104 8018; leedswest.rec{at}hra.nhs.uk), ref: 18/YH/0380 (approved as substantial amendment 02 under existing NIHR IRAS249030 research programme).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Declared competing interests of authors: none
Liz Littlewood: liz.littlewood{at}york.ac.uk
Dean McMillan: dean.mcmillan{at}york.ac.uk
Carolyn Chew-Graham: c.a.chew-graham{at}keele.ac.uk
Della Bailey: della.bailey{at}york.ac.uk
Samantha Gascoyne: samantha.gascoyne{at}york.ac.uk
Nick Meader: nick.meader{at}newcastle.ac.uk
Elizabeth Eddy: elizabethseddy2006{at}gmail.com
Nisha Hicklin nisha.hickin{at}gmail.com
Paul Heron: paul.heron{at}york.ac.uk
Claire Sloan: clairesloan21{at}gmail.com
Lauren Burke: lauren.burke{at}york.ac.uk
Peter Coventry: peter.coventry{at}york.ac.uk
Suzanne Crosland: Suzanne.crosland{at}york.ac.uk
Caroline Fairhurst: caroline.fairhurst{at}york.ac.uk
Andrew Henry: andrew.henry2{at}nhs.net
Catherine Hewitt: Catherine.hewitt{at}york.ac.uk
Kalpita Baird: kalpita.baird{at}york.ac.uk
Eloise Ryde: eloise.ryde{at}nhs.net
Leanne Shearsmith: L.Shearsmith{at}leeds.ac.uk
Osvaldo P. Almeida: osvaldo.almeida{at}uwa.edu.au
Gemma Traviss-Turner: g.traviss{at}leeds.ac.uk
Rebecca Woodhouse: rebecca.woodhouse{at}york.ac.uk
Roz Shafran r.shafran{at}ucl.ac.uk
Andrew Clegg: A.P.Clegg{at}leeds.ac.uk
Tom Gentry: Tom.Gentry{at}ageuk.org.uk
Andrew Hill: A.J.Hill{at}leeds.ac.uk
Karina Lovell: karina.lovell{at}manchester.ac.uk
Sarah Dexter Smith: sarah.dexter-smith{at}nhs.net
Judith Webster: ja.webster{at}hotmail.co.uk
David Ekers: david.ekers{at}nhs.net
Simon Gilbody: simon.gilbody{at}york.ac.uk
Data Availability
The BASIL research collective is especially keen that the BASIL data contributes to prospective meta-analyses and individual patient data meta-analyses. Requests for data sharing will be considered by the independent trial steering and data monitoring committee. Full underlying (non-aggregated) data cannot be made publicly available since the ethics approval of this study does not cover openly publishing non-aggregated data.
